Background: Numerous studies have suggested a possible role for acute kidney injury (AKI) biomarkers in predicting renal recovery both before and after renal replacement therapy (RRT). However, definitions for recovery and whether to include patients dying but free of RRT may influence results. Objectives: To validate plasma neutrophil gelatinase-associated lipocalin (pNGAL) as a useful biomarker for predicting or improving the ability of clinical predictors alone to predict recovery following AKI, including in our model plasma B-type natriuretic peptide (pBNP) to account for cardiovascular events. Methods: We analyzed 69 patients enrolled in the Acute Renal Failure Trial Network study. pNGAL and pBNP were measured on days 2, 7, and 14. We analyzed their predictive ability for subsequent recovery, defined as alive and independent from dialysis in 60 days. In sensitivity analyses, we explored changes in results with alternative definitions of recovery. Results: Twenty-nine patients (42%) recovered from AKI. Neither pNGAL nor pBNP, alone or in combination, was accurate predictors of renal recovery-the best area under the receiver-operating characteristics curve (AUC) was for pNGAL using the largest relative change (AUC 0.59, 95% CI 0.45–0.74). The best clinical model achieved superior performance to biomarkers (AUC 0.69, 95% CI 0.56–0.81). The AUC was greatest (0.75, 95% CI 0.60–0.91) when pNGAL + pBNP on day 14 were added to the clinical model but this increase did not achieve statistical significance. However, integrated discrimination improvement analysis showed that the addition of pNGAL and pBNP on day 14 to the clinical model significantly improved the prediction of renal recovery (p = 0.008). Conclusions: pNGAL and pBNP can improve the accuracy of clinical parameters in predicting AKI recovery and a full model using biomarkers together with age achieved adequate discrimination.

1.
Koraishy FM, Coca SG. Can we predict recovery from severe acute kidney injury with biomarkers?
Semin Dial
. 2014 May–Jun;27(3):236–9.
2.
Godin M, Macedo E, Mehta RL. Clinical determinants of renal recovery.
Nephron Clin Pract
. 2014;127(1–4):25–9.
3.
Goldstein SL, Chawla L, Ronco C, Kellum JA. Renal recovery.
Crit Care
. 2014 Jan;18(1):301.
4.
Kellum JA. How can we define recovery after acute kidney injury? Considerations from epidemiology and clinical trial design.
Nephron Clin Pract
. 2014;127(1–4):81–8.
5.
Srisawat N, Murugan R, Lee M, Kong L, Carter M, Angus DC, et al.; Genetic and Inflammatory Markers of Sepsis (GenIMS) Study Investigators. Plasma neutrophil gelatinase-associated lipocalin predicts recovery from acute kidney injury following community-acquired pneumonia.
Kidney Int
. 2011 Sep;80(5):545–52.
6.
Srisawat N, Murugan R, Kellum JA. Repair or progression after AKI: a role for biomarkers?
Nephron Clin Pract
. 2014;127(1–4):185–9.
7.
Endre ZH. Recovery from acute kidney injury: the role of biomarkers.
Nephron Clin Pract
. 2014;127(1–4):101–5.
8.
Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review.
Kidney Int
. 2008 May;73(9):1008–16.
9.
Srisawat N, Wen X, Lee M, Kong L, Elder M, Carter M, et al. Urinary biomarkers and renal recovery in critically ill patients with renal support.
Clin J Am Soc Nephrol
. 2011 Aug;6(8):1815–23.
10.
Chawla LS, Amdur RL, Shaw AD, Faselis C, Palant CE, Kimmel PL. Association between AKI and long-term renal and cardiovascular outcomes in United States veterans.
Clin J Am Soc Nephrol
. 2014 Mar;9(3):448–56.
11.
Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D, et al.; VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury.
N Engl J Med
. 2008 Jul;359(1):7–20.
12.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
JAMA
. 2016 Feb;315(8):801–10.
13.
Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults.
Chest
. 1991 Dec;100(6):1619–36.
14.
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.
Intensive Care Med
. 1996 Jul;22(7):707–10.
15.
Thakar CV, Arrigain S, Worley S, Yared JP, Paganini EP. A clinical score to predict acute renal failure after cardiac surgery.
J Am Soc Nephrol
. 2005 Jan;16(1):162–8.
16.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis
. 1987;40(5):373–83.
17.
Doyle JF, Forni LG. Long-Term Follow-up of Acute Kidney Injury.
Crit Care Clin
. 2015 Oct;31(4):763–72.
18.
Kellum JA. Diagnostic Criteria for Acute Kidney Injury: present and Future.
Crit Care Clin
. 2015 Oct;31(4):621–32.
19.
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter. 2012;2(2 Suppl):1–138.
20.
Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al.; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study.
JAMA
. 2005 Aug;294(7):813–8.
21.
Kellum JA, Chawla LS, Keener C, Singbartl K, Palevsky PM, Pike FL, et al.; ProCESS and ProGReSS-AKI Investigators. The Effects of Alternative Resuscitation Strategies on Acute Kidney Injury in Patients with Septic Shock.
Am J Respir Crit Care Med
. 2016 Feb;193(3):281–7.
22.
Ling W, Zhaohui N, Ben H, Leyi G, Jianping L, Huili D, et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography.
Nephron Clin Pract
. 2008;108(3):c176–81.
23.
Lipcsey M, Hayward P, Haase M, Haase-Fielitz A, Eastwood G, Peck L, et al. Neutrophil gelatinase-associated lipocalin after off pump versus on pump coronary artery surgery.
Biomarkers
. 2014 Feb;19(1):22–8.
24.
Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery.
Lancet
. 2005 Apr;365(9466):1231–8.
25.
Huang CY, Shih CC, Chung K, Kao KC, Wu HP. Predictive value of plasma neutrophil gelatinase-associated lipocalin for acute renal failure in patients with severe sepsis.
J Chin Med Assoc
. 2016 Aug;79(8):428–34.
26.
Kusaka M, Iwamatsu F, Kuroyanagi Y, Nakaya M, Ichino M, Marubashi S, et al. Serum neutrophil gelatinase associated lipocalin during the early postoperative period predicts the recovery of graft function after kidney transplantation from donors after cardiac death.
J Urol
. 2012 Jun;187(6):2261–7.
27.
Liu Y, Li HX, Ying ZW, Guo JJ, Cao CY, Jia W, et al. Serum Neutrophil Gelatinase-Associated Lipocalin and Cystatin C for Assessing Recovery of Graft Function in Patients Undergoing Living-Donor Kidney Transplantation.
Clin Lab
. 2016;62(1–2):155–63.
28.
Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al.; GenIMS Investigators. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study.
Arch Intern Med
. 2007 Aug;167(15):1655–63.
29.
Palazzuoli A, Ruocco G, Pellegrini M, De Gori C, Del Castillo G, Franci B, et al. Comparison of Neutrophil Gelatinase-Associated Lipocalin Versus B-Type Natriuretic Peptide and Cystatin C to Predict Early Acute Kidney Injury and Outcome in Patients With Acute Heart Failure.
Am J Cardiol
. 2015 Jul;116(1):104–11.
30.
Howell E, Sen S, Palmieri T, Godwin Z, Bockhold J, Greenhalgh D, et al. Point-of-care B-type natriuretic peptide and neutrophil gelatinase-associated lipocalin measurements for acute resuscitation: a pilot study.
J Burn Care Res
. 2015 Mar-Apr;36(2):e26–33.
31.
Palevsky PM, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, et al. Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology.
Clin J Am Soc Nephrol
. 2012 May;7(5):844–50.
32.
Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, et al.; Acute Disease Quality Initiative Workgroup 16. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup.
Nat Rev Nephrol
. 2017 Apr;13(4):241–57.
33.
Bihorac A, Chawla LS, Shaw AD, Al-Khafaji A, Davison DL, Demuth GE, et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication.
Am J Respir Crit Care Med
. 2014 Apr;189(8):932–9.
34.
Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury.
Crit Care
. 2013 Feb;17(1):R25.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.